■ Hanmi Pharmaceutical announced on the 2nd that it will hold a contest to name its obesity drug "efeglrenatide." The new drug is a long-acting GLP-1 receptor agonist that applies the proprietary platform "LabDiscovery." GLP-1 is a hormone secreted from the intestines when food is consumed. It helps suppress appetite by promoting insulin secretion that regulates blood glucose levels. A call for submissions is open until the 16th for doctors nationwide who are registered on Hanmi Pharmaceutical's medical portal "HMP."
■ Hallym University Chuncheon Sacred Heart Hospital announced on the 2nd that it recently held a blood donation event called "Life Sharing, Love Donation." Forty-seven faculty members and patients participated, collecting 16,480 cc of blood. The blood will be used for patients in need of transfusions, with some donated to the Korean Red Cross. The hospital has held annual blood donation events since 2004 to assist patients facing difficulties in securing blood.
■ Daewon Pharmaceutical announced on the 2nd that it received the Minister of Health and Welfare Award at the "2025 Bio Health Industry Commercialization Experts Award Ceremony." The company was recognized for its contributions to the Inter-Biz Bio Partnering Investment Forum, which includes 16 institutions, such as the Korea Drug Research Association. The company achieved transfer results by participating in the forum.
■ Merck Healthcare announced on the 2nd that it held an in-house talk concert with patients suffering from metastatic urothelial carcinoma. The event was held ahead of the second anniversary of health insurance coverage for the treatment of localized advanced or metastatic urothelial carcinoma drug Bavencio (active ingredient: avelumab).
■ EuBiologics announced on the 2nd that the Commissioner of the Seoul Food and Drug Administration, Ahn Young-jin, visited its second plant located in Chuncheon, Gangwon Province. He inspected the vaccine production facility and quality control system. The company introduced the licensing procedures encountered in overseas market entry and requested the government to improve regulations.
■ RP Bio announced on the 2nd that it has received a domestic patent for a combination formulation of probiotics and functional oils. It created capsules containing lactic acid bacteria and high-concentration edible oil. Each capsule can contain up to 100 billion lactic acid bacteria. The lactic acid bacteria can survive for 18 months at room temperature.
■ Oscotec announced on the 2nd that it has appointed former Executive Director Shin Dong-jun as Chief Financial Officer (CFO). He joined Korea Investment & Securities in 1999 and has since served as the head of KB Securities' research center and the investment strategy division. The company plans to promote a reasonable management system while communicating with shareholders.